Pharmaceutical Israeli drugmaker Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Swedish partner Active Biotech (Nordic: ACTI) yesterday revealed positive initial results from the two-year Phase III ALLEGRO study, which demonstrated that relapsing-remitting multiple sclerosis (MS) patients treated with 0.6mg daily oral laquinimod experienced a statistically significant reduction in annualized relapse rate compared to placebo. Additional clinical endpoints, including significant reduction in disability progression, as measured by Expanded Disability Severity Scale (EDSS), were also achieved. 10 December 2010